Background
Methods
Search strategy and selection criteria
Data extraction and quality assessment
Data synthesis and analysis
Results
Eligible studies
Authors and trial name | Trial type and location | Objective | Year | N T/C | Study population | LDL-C at follow up | LDL-C reducing percentage | Treatments | Follow up | Main Results or Conclusion |
---|---|---|---|---|---|---|---|---|---|---|
Okazaki S11; ESTABLISH | RCT: prospective, open-label, randomized, single center study. Japan | Effects of statins on changes in plaque by IVUS | 2004 | 24/24 | ACS | 70/119 | −44/-0.004 | Ato 20 vs Diet | 6 | Plaque volume was sigificantly reduced in the Ato group compared with the control group. |
Nissen SE10; REVERSAL | RCT: Double-blind, randomized active control multicenter trial; USA | Effects of statins (intensive or moderate) on changes in plaque by IVUS | 2004 | 253/249 | CAD | 79/110 | −46/-25 | Ato 80 vs Pra40 | 18 | Ato reduced progression of coronary plaque compared with Pra. Compared with baseline values, Ato had no change in atheroma burden, whereas patients treated with Pra showed progression of coronary plaque. |
Tardif JC5; A-PLUS | RCT: international, multicenter, double-blind, placebo-controlled, randomized trial. Canada, USA | Effects of different dosage of avasimibe on changes in plaque by IVUS | 2004 | 108/98/117/109 | CAD | 100/102/101/91 | 7.8/9.1/10.9/1.7 | Ava50, 250, and 750 vs Placebo on the basis of LDL-C < 125 | 18 | Avasimibe did not favorably alter coronary atherosclerosis as assessed by IVUS. |
Jensen LO28 | Open non placebo controlled serial investigation; blinded end-points. Denmark | To investigate the effect of lipid lowering by simvastatin on coronary atherosclerotic plaque volumes and lumen. | 2004 | 40 | CAD | 85 | −46.3 | Sim 40 | 15 | Lipid-lowering therapy with Sim is associated with a significant plaque regression in coronary arteries. |
Yokoyama M12 | RCT: randomized, single center. Japan | Effects of statins on changes in plaque by IVUS | 2005 | 29/30 | stabl angina | 87/124 | −35/-0.075 | Ato 10 vs Diet | 6 | Treatment with Ato may reduce volumes of coronary plaques. |
Kawasaki M13 | RCT: randomization, open-label, single-center study. Japan | Effects of statins on changes in plaque by IVUS | 2005 | 17/18/17 | stable angina | 95/102/149 | −39/-32/-0.02 | Ato 20, Pra 20 vs Diet | 6 | Treatment with Ato and Pra may not significantly reduce volumes of coronary plaques. |
Tani S22 | RCT: a prospective, single-center, randomized, open trial. Japan | Investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis. | 2005 | 52/23 | stable angina | 104/120 | −20/-2.4 | Pra 10–20 vs con | 6 | Plaque volume was sigificantly reduced in the Pra group compared with the control group. |
Nissen SE6; ACTIVATE | RCT: randomized, multicenter. USA | Effects of pactimibe on changes in plaque by IVUS | 2006 | 206/202 | CAD | 91/86 | −9.6/-14.9 | Pac100 vs Placebo | 18 | Pac is not an effective strategy for limiting atherosclerosis and may promote atherogenesis. |
Nissen SE26; ASTEROID | Prospective, open-label blinded end-points. USA, Germany, France, Canada | Effects of Statins with different levels of LDL-C on changes in plaque by IVUS | 2006 | 349 | CAD | 61 | −53.2 | Ros 40 | 24 | Therapy using Ros can result in significant regression of atherosclerosis. |
Yamada T14; REACH | RCT: open-labeled, randomized, multicenter study. Japan | Evaluate the effect of marked reduction of LDL-C in patients with CHD on progression of atherosclerosis. | 2007 | 26/32 | stable angina | 83/115 | −43/0 | Ato 5 vs Con | 12 | Ato treatment prevented the further progression of atherosclerosis by maintaining LDL-C below 100 mg/dl in patients with CHD. |
Nissen SE7; ILLUSTRATE | RCT: prospective, randomized, multicenter, double-blind clinical trial. North America or Europe | Effects of CETP inhibitor on changes in plaque by IVUS | 2007 | 446/464 | CAD | 87/70 | 6.6/-13.3 | Ato10-80 vs Ato + Tor 60 on the basis of LDL-C ≤ 100 by Ato | 24 | The Tor was associated with a substantial increase in HDL-C and decrease in LDL –C, and there was no significant decrease in the progression of coronary atherosclerosis. |
Nissen SE25; PERISCOPE | RCT: prospective, randomized, multicenter, double-blind clinical trial. USA | To compare the effects of pioglitazone, and glimepiride on the progression of coronary atherosclerosis in patients with type 2 diabete and CAD | 2008 | 181/179 | CAD,DM | 96.1/95.6 | 1.8/2.2 | Gli1-4 mg vs Pio 15-45 mg on bases of statins therapy | 18 | In patients with type 2 diabetes and CAD, treatment with Pio resulted in a significantly lower rate of progression of coronary atherosclerosis compared with Gli. |
Nissen SE24; STRADIVARIUS | RCT: Randomized, double-blinded, placebo -controlled, 2-group, parallel-group trial. North America, Europe, and Australia | The effect of rimonabant on regression of coronary disease in patients with the metabolic syndrome and CAD | 2008 | 335/341 | CAD,Obesity | 87.6/86.3 | −4.7/-3.6 | Rim 20 mg vs Placebo on bases of statins therapy | 18 | Rim can reduce progression of coronary plaque, and increase HDL-C levels, decrease triglyceride levels. |
Hiro T20; JAPAN-ACS | RCT: prospective, randomized, open-label, parallel group, multicenter. Japan | Effects of statins on changes in plaque by IVUS | 2009 | 127/125 | ACS | 84/81 | −36/-36 | Ato 20 vs Pit 4 | 10 | The administration of Pit or Ato in patients with ACS equivalently resulted in significant regression of coronary plaque volume. |
Takayama T; COSMOS29 | Prospective, open-label blinded end-points multicenter trial. Japan | Evaluate the effect of rosuvastatin on plaque volume in patients with stable CAD, including those receiving prior lipid-lowering therapy | 2009 | 126 | stable angina | 83 | −38.6 | Ros <20 | 14 | Ros exerted significant regression of coronary plaque volume in Japanese patients with stable CAD. |
Rodés-Cabau; ERASE23 | RCT: multicenter randomized placebo-controlled. Canada | Evaluate the early effects of newly initiated statin therapy on coronary atherosclerosis as evaluated by IVUS. | 2009 | 38/36 | ACS | 77/63 | 8.5/-37 | Before ACS vs After ACS | <2 | Newly initiated statin therapy is associated with rapid regression of coronary atherosclerosis. |
Nasu K30 | Prospective and multicenter study with nonrandomized and non-blinded design, but blinded end. Japan | Evaluate the effect of treatment with statins on the progression of coronary atherosclerotic plaques of a nonculprit vessel by serial IVUS. | 2009 | 40/39 | stable angina | 98.1/121 | −32.3/-1.1 | Flu 60 vs Con | 12 | One-year lipid-lowering therapy by Flu showed significant regression of plaque volume. |
Hong MK15 | RCT: randomized control trial. Korea. | Evaluated the effects of statin treatments for each component of coronary plaques. | 2009 | 50/50 | stable angina | 78/64 | −34.5/-44.8 | Sim 20 vs Ros 10 | 12 | Statin treatments might be associated with significant changes in necrotic core and fibrofatty plaque volume. |
Nicholls SJ; SATURN16 | RCT: a prospective, randomized, multicenter, double-blind clinical trial. USA | Compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis. | 2011 | 519/520 | CHD | 70.2/62.6 | −41.5/-47.8 | Ato 80 vs Ros 40 | 24 | Maximal doses of Ros and Ato resulted in significant regression of coronary atherosclerosis. |
Lee CW17; ARTMAP | RCT: a prospective, single-center, open-label, randomized comparison trial. Korea. | Compared the effects of atorvastatin 20 mg/day versus rosuvastatin 10 mg/day on mild coronary atherosclerotic plaques. | 2012 | 143/128 | stable angina | 56/53 | −47/-49 | Ato 20 vs Ros 10 | 6 | Usual doses of Ato and Ros induced significant regression of coronary atherosclerosis in statin-naive patients. |
Authors | Trial name | Management in each arm | N | LDL-C level | |
---|---|---|---|---|---|
At baseline | At follow-up | ||||
Tardif JC | A-PLUS | Avasimibe50 | 108 | 92.8 ± 1.7 | 100* |
Tardif JC | A-PLUS | Avasimibe250 | 98 | 93.4 ± 1.6 | 101.9* |
Tardif JC | A-PLUS | Avasimibe750 | 117 | 91.4 ± 1.6 | 101.4* |
Tardif JC | A-PLUS | Placebo | 109 | 89.6 ± 1.6 | 91.1* |
Okazaki S | ESTABLISH | Control | 24 | 123.9 ± 35.3 | 119.4 ± 24.6 |
Okazaki S | ESTABLISH | Atorvastatin | 24 | 124.6 ± 34.5 | 70.0 ± 25.0 |
Yokoyama M | Control | 30 | 131.5 ± 23# | 124.5 ± 24.1# | |
Yokoyama M | Atorvastatin | 29 | 133 ± 13 | 87 ± 29 | |
Nissen SE | REVERSAL | Atorvastatin | 253 | 150.2 ± 27.9 | 78.9 ± 30.2 |
Nissen SE | REVERSAL | Pravastatin | 249 | 150.2 ± 25.9 | 110.4 ± 25.8 |
Nissen SE | ACTIVATE | Pactimibe | 206 | 101.4 ± 27.7 | 91.3 |
Nissen SE | ACTIVATE | Placebo | 202 | 101.5 ± 31.1 | 86.4 |
Nissen SE | ILLUSTRATE | Atorvastatin | 446 | 84.3 ± 18.9 | 87.2 ± 22.6 |
Nissen SE | ILLUSTRATE | Atorva + torcetrapib | 464 | 83.1 ± 19.7 | 70.1 ± 25.4 |
Kawasaki M | Control | 17 | 152 ± 20 | 149 ± 24 | |
Kawasaki M | Pravastatin | 18 | 149 ± 19 | 102 ± 13 | |
Kawasaki M | Atorvastatin | 17 | 155 ± 22 | 95 ± 15 | |
Hiro T | JAPAN-ACS | Pitavastatin | 125 | 130.9 ± 33.3 | 81.1 ± 23.4 |
Hiro T | JAPAN-ACS | Atorvastatin | 127 | 133.8 ± 31.4 | 84.1 ± 27.4 |
Nissen SE | ASTEROID | Rosuvastatin | 349 | 130.4 ± 34.3 | 60.8 ± 20.0 |
Takayama T | COSMOS | Rosuvastatin | 126 | 140.2 ± 31.5 | 82.9 ± 18.7 |
Lee CW | ARTMAP | Atorvastatin | 143 | 110 ± 31 | 56 ± 18 |
Lee CW | ARTMAP | Rosuvastatin | 128 | 109 ± 31 | 53 ± 18 |
Yamada T | REACH | Atorvastatin | 26 | 123 ± 17 | 83 ± 22 |
Yamada T | REACH | Control | 32 | 115 ± 14 | 115 ± 30 |
Nasu K | Fluvastatin | 40 | 144.9 ± 31.5 | 98.1 ± 12.7 | |
Nasu K | Control | 39 | 122.3 ± 18.9 | 121.0 ± 21.2 | |
Nicholls SJ | SATURN | Atorvastatin | 519 | 119.9 ± 28.9 | 70.2 ± 1.0 |
Nicholls SJ | SATURN | Rosuvastatin | 520 | 120.0 ± 27.3 | 62.6 ± 1.0 |
Hong MK | Simvastatin | 50 | 119 ± 30 | 78 ± 20 | |
Hong MK | Rosuvastatin | 50 | 116 ± 28 | 64 ± 21 | |
Tani S | Pravastatin | 52 | 130 ± 38 | 104 ± 20 | |
Tani S | Control | 23 | 123 ± 28 | 120 ± 30 | |
Rodés-C Bef | ERASE | Statins before ACS | 38 | 71 ± 23 | 77 ± 25 |
Rodés-C Aft | ERASE | Statins after ACS | 36 | 100 ± 30 | 63 ± 17 |
Jensen LO | Simvastatin | 40 | 158.7 ± 30.6 | 85.1 ± 22.1 | |
Nissen SE | PERISCOPE | Statins + Gli | 181 | 94.4 ± 32.9 | 96.1 ± 30.4 |
Nissen SE | PERISCOPE | Statins + Pio | 179 | 93.5 ± 30.7 | 95.6 ± 28.9 |
Nissen SE | STRADIVARIUS | Statins + Rim | 335 | 91.9 ± 27.9 | 87.6 ± 30.5 |
Nissen SE | STRADIVARIUS | Statins + Con | 341 | 89.5 ± 32.2 | 86.3 ± 30.3 |
The effect of the levels of LDL-C at follow-up on regression of coronary atherosclerotic plaque in Western and Asian
Group | Included arms (case) | CAP volume at baseline (mm3) | CAP volume at follow up (mm3) | Pooled SMD (95% CI,p) | Heterogeneity test | Sensitivity analyses | Egger’s test | |||
---|---|---|---|---|---|---|---|---|---|---|
χ
2
test (p) |
I
2
| Lower SMD (95% CI) | Upper SMD (95% CI) | |||||||
Western | <70 mg | 3(905) | 171.4 ± 32.7 | 160.6 ± 29.7 | −0.156(−0.248 ~ −0.064, 0.001) | 0.33(0.886) | 0 | −0.139 (−0.257 ~ −0.021) Without 2006 ASTEROID Ros | −0.175 (−0.317 ~ −0.034) Without 2011 SATURN Ros | 0.789 |
>70 ≤ 100 HPmg | 3(812) | 151.9 ± 30.4 | 147.9 ± 31.9 | −0.065(−0.136 ~ 0.032, 0.189) | 0.71(0.699) | 0 | 0.987 | |||
>70 ≤ 100 MPmg | 5(1548) | 195.8 ± 2.3 | 191.8 ± 4.7 | −0.045(−0.115 ~ −0.026, 0.215) | 1.59(0.811) | 0 | 0.500 | |||
>70 ≤ 100 LPmg | 6(1061) | 201.2 ± 15.1 | 197.3 ± 15.0 | −0.045(−0.130 ~ 0.040, 0.301) | 1.14(0.950) | 0 | 0.241 | |||
>100 mg | 3(464) | 197.6 ± 3.5 | 201.1 ± 1.9 | 0.034(−0.094 ~ 0.163, 0.601) | 0.03(0.984) | 0 | ||||
>50% | 1(349) | 212.2 ± 81.3 | 197.5 ± 79.1 | −0.183(−0.332 ~ −0.035, 0.016) | ||||||
>40 ≤ 50% | 4(1332) | 148.8 ± 24.0 | 143.1 ± 25.6 | −0.095(−0.171 ~ −0.019, 0.014) | 1.64(0.651) | 0 | −0.065 (−0.163 ~ 0.032) Without 2011 SATURN Ros | −0.116 (−0.201 ~ −0.032) Without 2004 REVERSAL Ato | 0.804 | |
>30 ≤ 40% | 1(36) | 169.1 ± 77.3 | 161.5 ± 75.2 | −0.099(−0.561 ~ 0.363, 0.675) | 0.00(0.000) | 0 | ||||
>0 ≤ 30% | 6(1797) | 195.6 ± 2.1 | 192.9 ± 5.1 | −0.032(−0.098 ~ 0.033, 0.335) | 2.45(0.784) | 0 | ||||
<0% | 8(1276) | 201.2 ± 13.8 | 198.3 ± 13.8 | −0.034(−0.111 ~ 0.044, 0.396) | 1.55(0.981) | 0 | 0.087 | |||
Asian | <70 mg | 4(345) | 192.2 ± 59.9 | 179.9 ± 53.0 | −0.157(−0.307 ~ −0.008, 0.039) | 0.24(0.955) | 0 | −0.126 (−0.314 ~ 0.063) Without 2012 ARTMAP Ros | −0.187 (−0.383 ~ 0.008) Without 2012 ARTMAP Ato | 0.970 |
>70 ≤ 100 HPmg | 8(540) | 96.4 ± 99.3 | 87.5 ± 92.0 | −0.211(−0.331 ~ −0.092, 0.001) | 2.68(0.913) | 0 | −0.177 (−0.314 ~ −0.040) Without 2009 JAPAN-ACS Ato | −0.231(−0.368 ~ −0.094) Without 2009 COSMOS Ros | 0.083 | |
>100 mg | 8(235) | 133.0 ± 139.6 | 134.3 ± 143.8 | −0.029(−0.210 ~ 0.152, 0.750) | 2.14(0.952) | 0 | ||||
>40 ≤ 50% | 4(345) | 192.2 ± 56.9 | 179.9 ± 53.0 | −0.157(−0.307 ~ −0.008, 0.039) | 0.33(0.955) | 0 | −0.126 (−0.314 ~ 0.063) Without 2012 ARTMAP Ros | −0.187 (−0.383 ~ 0.008) Without 2012 ARTMAP Ato | 0.970 | |
>30 ≤ 40% | 9(558) | 98.6 ± 98.5 | 90.0 ± 91.6 | −0.206(−0.324 ~ −0.088, 0.001) | 2.91(0.840) | 0 | −0.172 (−0.306 ~ −0.038) Without 2009 JAPAN-ACS Ato | −0.223 (−0.357 ~ −0.089) Without 2009 COSMOS Ros | 0.004 | |
>0 ≤ 30% | 7(217) | 130.2 ± 144.9 | 131.8 ± 149.4 | −0.028(−0.216 ~ 0.161, 0.773) | 2.14(0.907) | 0 |
The effect of the LDL-C reducing percentage at follow-up on regression of CAP in Western and Asian
Group | N | Mean LDL-C at baseline (mg) | Mean LDL-C at follow up (mg) | Mean reducing percentage | Actual range of reducing percentage | Duration (month) | |
---|---|---|---|---|---|---|---|
Western | ≤70 mg | 905 | 123.2 ± 6.9 | 61.9 ± 0.9 | 49.4 ± 3.5 | 37 ~ 53 | 23.1 ± 4.3 |
>70 ≤ 100 HPmg | 812 | 131.3 ± 15.2 | 73.6 ± 4.8 | 43.2 ± 2.2 | 41.5 ~ 46.7 | 21.7 ± 3.1 | |
>70 ≤ 100 MPmg | 1548 | 91.3 ± 6.9 | 82.4 ± 8.2 | 9.0 ± 4.5 | 3.6 ~ 14.9 | 19.8 ± 2.7 | |
>70 ≤ 100 LPmg | 1061 | 88.5 ± 5.5 | 91.5 ± 5.4 | −4.7 ± 2.5 | −1.7 ~ −8.5 | 19.9 ± 4.5 | |
>100 mg | 464 | 123.4 ± 28.9 | 106.3 ± 4.4 | 8.7 ± 17.5 | −10.9 ~ 25.0 | 18.0 ± 0.0 | |
>50% | 349 | 130.4 ± 0.0 | 60.8 ± 0.0 | 53.4 ± 0.0 | 53.4 ~ 53.4 | 24.0 ± 0.0 | |
>40 ≤ 50% | 1332 | 126.9 ± 13.1 | 69.3 ± 6.5 | 45.0 ± 2.8 | 41.5 ~ 47.8 | 22.6 ± 2.7 | |
>30 ≤ 40% | 36 | 100.2 ± 30.2 | 63.1 ± 17.4 | 37.0 | 37 ~ 37 | 2.0 ± 0.0 | |
>0 ≤ 30% | 1797 | 99.4 ± 21.4 | 86.2 ± 12.2 | 11.2 ± 6.9 | 3.6 ~ 25.0 | 19.5 ± 2.6 | |
<0% | 1276 | 89.1 ± 5.3 | 93.2 ± 6.2 | −5.6 ± 3.1 | −1.7 ~ −10.9 | 19.6 ± 4.2 | |
Asian | ≤70 mg | 345 | 111.5 ± 4.3 | 57.0 ± 5.0 | 47.2 ± 1.7 | 44 ~ 49 | 6.9 ± 2.1 |
>70 ≤ 100 HPmg | 540 | 134.2 ± 7.8 | 84.0 ± 5.0 | 36.1 ± 1.8 | 32.3 ~ 39.0 | 11.0 ± 2.2 | |
>100 mg | 235 | 128.6 ± 10.5 | 117.2 ± 11.9 | 7.3 ± 10.7 | 0 ~ 32 | 7.8 ± 2.8 | |
>40 ≤ 50% | 345 | 111.5 ± 4.3 | 57.0 ± 5.0 | 47.2 ± 1.7 | 44 ~ 49 | 6.9 ± 2.1 | |
>30 ≤ 40% | 558 | 134.7 ± 8.1 | 84.6 ± 5.8 | 36.0 ± 1.9 | 32 ~ 39 | 10.9 ± 2.4 | |
>0 ≤ 30% | 217 | 126.9 ± 9.1 | 118.3 ± 11.5 | 5.3 ± 8.3 | 0 ~ 20.0 | 8.0 ± 2.8 |
The effect of lowering LDL-C by statins on regression of coronary atherosclerotic plaque in Western and Asian
Group | Included arms (and case) | Pooled SMD (95% CI,p) | Heterogeneity test | Sensitivity analyses | Egger’s test | |||
---|---|---|---|---|---|---|---|---|
χ
2
test (p) |
I
2
| Lower SMD (95% CI) | Upper SMD (95% CI) | |||||
Western | Rosuvastatin | 2(869) | −0.158(−0.253 ~ −0.064, 0.001) | 0.18(0.672) | 0 | −0.142 (−0.263 ~ −0.020) Without 2006 ASTEROID Ros | −0.183 (−0.332 ~ −0.035) Without 2011 SATURN Ros | 0.000 |
Atorvastatin | 2(772) | −0.062(−0.162 ~ 0.038, 0.225) | 0.62(0.432) | 0 | 0.000 | |||
Pravastatin | 1(249) | 0.045(−0.131 ~ 0.221, 0.616) | ||||||
Simvastatin | 1(40) | −0.133(−0.572 ~ 0.306, 0.552) | ||||||
Asian | Rosuvastatin | 3(304) | −0.172(−0.331 ~ −0.012, 0.035) | 0.17(0.917) | 0 | −0.143 (−0.352 ~ 0.066) Without 2012 ARTMAP Ros | −0.189 (−0.397 ~ 0.019) Without 2009 COSMOS Ros | 0.660 |
Atorvastatin | 6(366) | −0.185(−0.330 ~ −0.040, 0.013) | 1.94(0.858) | 0 | −0.113 (−0.292 ~ 0.068) Without 2009 JAPAN-ACS Ato | −0.230 (−0.417 ~ −0.044) Without 2012 ARTMAP Ato | 0.456 | |
Pravastatin | 2(70) | −0.197(−0.529 ~ 0.135, 0.245) | 0.26(0.608) | 0 | ||||
Pitavastatin | 1(125) | −0.304(−0.553 ~ −0.055, 0.017) | ||||||
Fluvastatin | 1(40) | −0.169(−0.608 ~ 0.270, 0.450) | ||||||
Simvastatin | 1(50) | −0.074(−0.467 ~ 0.318, 0.710) |
Group | N | Age | MeanLDL-C at baseline (mg) | MeanLDL-C at follow up (mg) | Mean reducing percentage | Statin dosage (mg) | Duration (month) | |
---|---|---|---|---|---|---|---|---|
Western | Rosuvastatin | 869 | 57.8 ± 0.6 | 124.2 ± 5.1 | 61.9 ± 0.9 | 49.9 ± 2.6 | 40.0 ± 0.0 | 24.0 ± 0.0 |
Atorvastatin | 772 | 57.2 ± 1.0 | 129.8 ± 14.2 | 73.1 ± 4.1 | 43.0 ± 2.1 | 80.0 ± 0.0 | 22.0 ± 2.8 | |
Pravastatin | 249 | 56.6 ± 0.0 | 150.2 ± 0.0 | 110.4 ± 0.0 | 25.0 ± 0.0 | 40.0 ± 0.0 | 18.0 ± 0.0 | |
Simvastatin | 40 | 57.7 ± 0.0 | 158.7 ± 0.0 | 85.1 ± 0.0 | 46.7 ± 0.0 | 40.0 ± 0.0 | 25.0 ± 0.0 | |
Asian | Rosuvastatin | 304 | 58.9 ± 3.3 | 123.1 ± 14.6 | 67.2 ± 13.8 | 44.0 ± 4.8 | 14.1 ± 4.9 | 10.3 ± 3.7 |
Atorvastatin | 366 | 60.9 ± 3.0 | 124.1 ± 12.7 | 72.9 ± 14.2 | 40.7 ± 5.5 | 18.9 ± 2.9 | 7.8 ± 2.2 | |
Pitavastatin | 125 | 62.5 ± 11.5 | 130.9 ± 33.3 | 81.1 ± 23.4 | 36.2 ± 19.5 | 4 | 8 ~ 12 | |
Pravastatin | 70 | 64.0 ± 1.8 | 134.9 ± 8.4 | 130.5 ± 0.9 | 23.1 ± 5.3 | 16.3 ± 2.2 | 6.0 ± 0.0 | |
Fluvastatin | 40 | 63.0 ± 10.0 | 144.9 ± 31.5 | 98.1 ± 12.7 | 32.3 | 60 | 12 | |
Simvastatin | 50 | 58.0 ± 0.0 | 119.0 ± 0.0 | 78.0 ± 0.0 | 34.5 ± 0.0 | 20.0 ± 0.0 | 12.0 ± 0.0 |
The difference between Western and Asian in usage of statins
Rosuvastatin | Atorvastatin | |||||
---|---|---|---|---|---|---|
Western | Asian | p | Western | Asian | p | |
N/arm | 869/2 | 304/3 | 772/2 | 366/6 | ||
Mean LDL-C at baseline (mg) | 124.2 ± 5.1 | 123.1 ± 14.6 | 0.928 | 129.8 ± 14.2 | 124.1 ± 12.7 | 0.610 |
Mean LDL-C at follow up (mg) | 61.9 ± 0.9 | 67.2 ± 13.8 | 0.642 | 73.1 ± 4.1 | 72.9 ± 14.2 | 0.986 |
LDL-C Mean reducing percentage | 49.9 ± 2.6 | 44.0 ± 4.8 | 0.221 | 43.0 ± 2.1 | 40.7 ± 5.5 | 0.600 |
Statin dosage (mg) | 40.0 ± 0.0 | 14.1 ± 4.9 | 0.006 | 80.0 ± 0.0 | 18.9 ± 2.9 | <0.001 |
Duration (month) | 24.0 ± 0.0 | 10.3 ± 3.7 | 0.016 | 22.0 ± 2.8 | 7.8 ± 2.2 | <0.001 |